Phase III Trial Of Radical Chemo-radiation Vs Radiation Alone In The Management Of Localised Bladder TCC.
Funder
National Health and Medical Research Council
Funding Amount
$194,875.00
Summary
This trial aims to see if the combination of Chemotherapy and Radiation treatment is indeed superior in eradicating the tumor and preserving the Bladder in a greater number of patients as compared to Radiation treatment alone. If the final results from this study do show chemoradiotherapy to be significantly superior to radiation alone, without an increase in morbidity ( especially long term side effects ) , this may lay the platform for a greater proportion of patients with localised bladder ca ....This trial aims to see if the combination of Chemotherapy and Radiation treatment is indeed superior in eradicating the tumor and preserving the Bladder in a greater number of patients as compared to Radiation treatment alone. If the final results from this study do show chemoradiotherapy to be significantly superior to radiation alone, without an increase in morbidity ( especially long term side effects ) , this may lay the platform for a greater proportion of patients with localised bladder cancer, being in the first instance considered for this organ( bladder) preserving approach something which has become a reality at a number of other sites of cancer with the use of multimodality treatment.Read moreRead less
The spread of cancer to other organs is responsible for 90% of cancer deaths. This proposal seeks to determine how urological tumours (prostate and bladder) spread around the body. Cancer cell and animal models are an integral component of the research, and together with data obtained in human cancer specimens provide a comprehensive, powerful approach to identify key pathways involved in tumour spread. This is critical for the design of new therapies to treat and-or prevent tumour spread.
I am a medical oncologist and tumour immunologist, dedicated to basic and translational clinical research particularly in the field of urological cancer and also in melanoma.
Methylation And The Risk Of Urothelial Cell Cancer
Funder
National Health and Medical Research Council
Funding Amount
$703,628.00
Summary
Why don’t we run prevention programs for urinary tract cancers like we do for others? It’s because we don’t know which lifestyle factors, except smoking, are important to cancers of the renal pelvis, ureters, bladder and urethra. We plan to use new technology to measure the ‘epigenome’, the part of the genome that turns genes on or off. This may explain how lifestyle factors influence what genes do, and we hope our findings will help to develop future prevention strategies for these cancers.
A Multi-Centre Feasibility Study Of Online Adaptive Image Guided Radiotherapy For Muscle Invasive Bladder Cancer
Funder
National Health and Medical Research Council
Funding Amount
$580,152.00
Summary
Many studies have shown that the bladder can move, change in size and shape through a course of radiation therapy. As shown in a pilot study, with the online adaptive radiotherapy technique trained staff can daily match the radiation fields to the bladder position and size using a type of CT scan. Potential benefits are better cancer coverage with improved cancer control and less normal tissue irradiation. This study will determine if the technique will work across multiple Australian centres.
Activating Transcription Factor 3 And Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$767,794.00
Summary
We have shown that the transcription factor ATF3 suppresses bladder cancer spread. Turning off ATF3 is associated with disease progression in bladder and colorectal cancer. We will test whether levels of ATF3 can be used as a prognostic maker for disease progression, investigate the mechanisms underlying the actions of ATF3 in bladder and colorectal cancer and test whether therapeutically activating ATF3 can inhibit cancer progression.